NCT06026878

GNT Induction Treatment in Locally Advanced NPC

Gemcitabine Combined With Nimotuzumab and Toripalimab as Induction Treatment Followed by Chemoradiotherapy for Locally Advanced Nasopharyngeal carcinoma-a Multicenter, Randomized Controlled Study

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 228 (estimated)
• Sponsor: Air Force Military Medical University, China · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	gemcitabine,nimotuzumab, toripalimab	same as before
DRUG	gemcitabine, cisplatin	same as before

Timeline

• Start date: 2023-09-01
• Primary completion: 2025-09-30
• Completion: 2027-09-30
• First posted: 2023-09-07
• Last updated: 2023-09-07

Locations

1 site across 1 country: China